-
5 days ago | 
dermatologytimes.com | Emma Andrus
Dermatology Times presents: Spot Test!Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the critical intersections between dermatologic conditions and psychological well-being in recognition of Mental Health Awareness Month. Do you have a set of quiz questions to share?
-
6 days ago | 
dermatologytimes.com | Emma Andrus
In a world where medicine continues to evolve rapidly across specialties, one thing remains constant: patients are more informed, curious, and discerning than ever before. In dermatology, arguably one of the most visual and patient-facing specialties, this creates opportunity and challenge. For S.
-
6 days ago | 
dermatologytimes.com | Emma Andrus |Seemal R. Desai
Earlier this year, Seemal Desai, MD, FAAD, concluded his term as president of the American Academy of Dermatology (AAD), marking a tenure defined by advocacy, unity, and vision for the future of the specialty. In an exclusive article for Dermatology Times, Desai recently outlined 3 pivotal issues that will shape dermatology in 2025 and beyond: Medicare reimbursement reform, board-certification awareness, and balancing technological advances with patient-centered care.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. The Clinical Image Collection enhances dermatologic education by providing diverse images of skin conditions, promoting inclusivity and accurate diagnoses across all skin tones. New research from AAD 2025 highlights upadacitinib's effectiveness over dupilumab for treating atopic dermatitis, especially in challenging facial and neck areas.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Explore the hidden health risks of nail products and the urgent need for safety reforms in the nail salon industry for workers and customers alike. Explore innovative strategies for managing alopecia areata with insights from expert Susan Taylor, MD, FAAD, highlighting breakthrough JAK inhibitors and real-world case studies.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
Skin Research and Technology: Short- and Long-Term Effects of Adding Topical Cosmetics to a Dermatological Procedure (Thermage): A Randomized Controlled Comparative Study Exploring the Synergistic EffectsA recent study examined the synergistic effects of dermatological procedures and cosmetic products on aging skin. Researchers evaluated the impact of Thermage treatment alone versus Thermage combined with anti-aging and repair-focused products in 42 women.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
A recent review published in the Journal of Drugs in Dermatology explored the potential cardioprotective and thromboprotective effects in upadacitinib, a selective JAK1 inhibitor, in patients with moderate to severe atopic dermatitis (AD).1While upadacitinib is primarily known for its efficacy in controlling skin inflammation,2 the review suggests it may also play a role in reducing the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE).
-
1 week ago | 
dermatologytimes.com | Emma Andrus
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference. Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
The State of Melanoma Care: Advances, Access, and the Road AheadThis Melanoma Monday, we take a look at melanoma care in the US, from treatments to persistent gaps in access, early detection, and long-term outcomes. Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
-
1 week ago | 
dermatologytimes.com | Emma Andrus |Christopher G. Bunick
In an interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, offered perspective on where investigational biologics targeting the OX40 and OX40 ligand (OX40L) pathway may eventually fit into the already complex atopic dermatitis (AD) treatment landscape. “It’s a complicated atopic dermatitis landscape right now,” Bunick said. “We obviously have the oral JAK inhibitors.
